Want to join the conversation?
Pharmaceutical company $ALXN delivered total YoverY revenue growth of 18% and volume growth of 23% in 2Q16, driven by the strength of its three marketed therapies. Soliris grew with a steady number of new patients with PNH and aHUS being treated globally. Strensiq is a new driver of growth and Kanuma continued to progress.
Keep your eyes on $FLXN. This one could ascend rapidly. Great time to buy your favourite bio stocks. Make more $$$
$CRM on the pop today.. big bubble.
Slumping and down the drain... $HDSN. Flush out your holdings !
$KITE I am loving this one... really flying like a kite today :-)